Billionaire Nicholas J. Pritzker's 8 Stocks with Huge Upside Potential
Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners, a San Francisco-based venture capital firm established in 2013.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paulson & Co John Paulson | 2,099,523 | $695,425,003 | +3% | 39.81% |
| 2. | VenBio Select Advisor Kurt Von Emster | 2,022,222 | $669,820,593 | -1% | 10.46% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,974,590 | $654,043,446 | 7.24% | |
| 4. | Holocene Advisors Brandon Haley | 390,545 | $129,360,220 | 0.38% | |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 317,433 | $105,143,333 | +3% | 0.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $229.86 | 3,960 | $910,264.21 | 1,793,403 | 2023-12-14 | Filing | |
| $229.86 | 316 | $72,637.25 | 185,979 | 2023-12-14 | Filing | |
| $228.79 | 2,204 | $504,251.62 | 1,789,443 | 2023-12-14 | Filing | |
| $228.79 | 176 | $40,266.92 | 185,663 | 2023-12-14 | Filing | |
| $227.86 | 11,602 | $2,643,596.91 | 1,787,239 | 2023-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $330.23 | 75 | $24,766.88 | 350,076 | 2025-03-13 | Filing | |
| $329.86 | 967 | $318,974.72 | 350,151 | 2025-03-13 | Filing | |
| $328.68 | 400 | $131,472.48 | 351,118 | 2025-03-13 | Filing | |
| $327.63 | 1,000 | $327,626.80 | 351,518 | 2025-03-13 | Filing | |
| $325.63 | 800 | $260,501.04 | 352,518 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,205,849 | $723,109,563 | 0.4% | |
| 2. | 1,993,687 | $660,368,945 | 10.1% | |
| 3. | 1,690,111 | $559,815,467 | 0.01% | |
| 4. | 1,486,460 | $492,360,146 | 0.01% | |
| 5. | 758,511 | $251,241,599 | 0.01% |
News See All
Billionaire John Paulson's 10 Stocks with Huge Upside Potential
John Alfred Paulson is an American billionaire hedge fund manager who founded Paulson & Co. in 1994. It is a New York-based fund management firm that specializes in private equity and hedge funds.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript February 26, 2025Madrigal Pharmaceuticals, Inc. beats earnings expectations.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript October 31, 2024Madrigal Pharmaceuticals, Inc. beats earnings expectations.
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and down compared to other stocks.
10 Best Guru Stocks To Buy Now
Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the right set of vehicles to either preserve or grow money can often seem to be a ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2024 Earnings Call Transcript August 7, 2024Madrigal Pharmaceuticals, Inc. beats earnings expectations.